Novo Nordisk's Wegovy wins FDA approval for heart health benefits, in move that could expand insurance coverage

Injection pens of Novo Nordisk's weight-loss drug Wegovy are shown in this photo illustration in Oslo, Norway, Nov. 21, 2023.The Food and Drug Administration approved Novo Nordisk's blockbuster weight loss drug Wegovy for use in slashing the risk of serious cardiovascular complications in people with obesity and heart disease, the company said Friday. That decision could widen insurance coverage for the drug and similar treatments for obesity, which has been a major barrier to access for patients. The appro ...